Long-Term Tolerability of Tetrabenazine in the Treatment of Hyperkinetic Movement Disorders

Christine B. Hunter, RN, and Kevin Dat Vuong, MA, and Joseph Jankovic, MD
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas

Abstract
Tourette syndrome (TS), dystonia, and other involuntary movement disorders, but the drug

INTRODUCTION

Objective: To review long-term tolerability of tetrabenazine (TBZ) in the treatment of

METHODS

RESULTS

During the period of January 1995 and January 2003, a total of 526 patients (394 males, 132 females) were treated with TBZ at the Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine. Of these patients, 149 had TS, 132 had dystonia, 98 had chorea, and 99 had tics. The average duration of treatment was 4.6 years (range: 0.0–21.6). Mean daily dose at last visit was 60.4 ± 35.7 mg (range: 0.0–210.0). At the last visit, 77.8% of patients had significant reduction in hyperkinetic movement disorder (TD = 83.5%, 85.7%; dystonia = 67.2%, 69.5%; chorea = 84.4%, 81.4%; tics = 76.7%, 77.8%; myoclonus = 76.5%, 71.4%). A subset (n = 132, 69.5%) of patients experienced reduction in all four hyperkinetic movement disorders except for dyskinesia.

CONCLUSION

TBZ is a safe and effective drug for a variety of hyperkinetic movement disorders, including TS, dystonia, tetanus, tuberculous meningitis, and lumbosacral plexus injury. The use of TBZ in the treatment of these conditions is supported by a) the long-term tolerability of TBZ in the treatment of movement disorders as demonstrated by previous studies, b) the efficacy of TBZ in the treatment of Parkinson's disease, c) the fact that TBZ is a centrally acting drug and is effective even when used in the treatment of movement disorders, d) the fact that TBZ is not a centrally acting drug and is effective even when used in the treatment of movement disorders, and e) the fact that TBZ is a centrally acting drug and is effective even when used in the treatment of movement disorders.

Table 1. Tetrabenazine Versus Reserpine

Table 2. Demographics among Patients with Hyperkinetic Movement Disorders Receiving Tetrabenazine Treatment

Table 3. Disease Severity by Indication

Table 4. TBZ Treatment Disposition

Table 5. Duration (Hours) of TBZ Treatment by Indication

Table 6. Adverse Event Profile Among Patients with Hyperkinetic Movement Disorders Receiving TBZ Treatment

Table 7. Comparison of Adverse Effects Profile by Tetrabenazine Treatment Tolerability Indication and Disposition

Table 8. Summary of Adverse Events

Figure 1. Tetrabenazine (TBZ) Vesicular Monoamine Transporter (VMAT)

Figure 2. Efficacy Response at Initial and Last Visit per Indication of TBZ Treatment

Figure 3. Tetrabenazine (TBZ) Treatment Indication and Disposition

Figure 4. Duration (Hours) of TBZ Treatment by Indication

Figure 5. Comparison of Adverse Effects Profile by Tetrabenazine Treatment Tolerability Indication and Disposition

Figure 6. Summary of Adverse Events

Figure 7. Tetrabenazine (TBZ) Medication Comparison

Figure 8. Tetrabenazine (TBZ) Medication Comparison

Figure 9. Tetrabenazine (TBZ) Medication Comparison

Figure 10. Tetrabenazine (TBZ) Medication Comparison